SCHEMBL24251980

SCHEMBL24251980

C#Cc1cc2nc(C)sc2cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
HSD17B10 Q99714 2/20 0.53
PKM P14618 2/20 0.53
ALDH1A1 P00352 2/20 0.53
TP53 P04637 1/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
GAA P10253 1/20 0.50
ALOX15 P16050 1/20 0.39
ATM Q13315 1/20 0.39
CHRNB2 P17787 1/20 0.38
CHRNA4 P43681 1/20 0.38
LDHA P00338 1/20 0.38
POLB P06746 2/20 0.37
TDP1 Q9NUW8 2/20 0.36
HTT P42858 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25604312 0.83 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHSD17B10PKM
SCHEMBL14297419 0.80 SMN1; SMN2 (0.68) SMN1; SMN2NPC1RAB9AHSD17B10PKM
SCHEMBL26086246 0.78 P2RX7 (0.31)
SCHEMBL30580446 0.78 P2RX7 (0.31)
SCHEMBL21606916 0.77 GAA (0.70) SMN1; SMN2NPC1RAB9AHSD17B10PKM
SCHEMBL24251906 0.75 NPC1 (0.38) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL21604553 0.74 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHSD17B10PKM
SCHEMBL21882016 0.74 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHSD17B10PKM
SCHEMBL4384430 0.73 SMN1; SMN2 (0.85) SMN1; SMN2NPC1RAB9AHSD17B10PKM
SCHEMBL24251984 0.73 NPC1 (0.36) NPC1RAB9AALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 US disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 US disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 EP disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 EP disclosed
WO-2022042612-A1 DIHYDROPYRROLO[2,3-D]PYRIDAZIN-7-ONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海和誉生物医药科技有限公司 2022-03-03 WO disclosed
WO-2022033532-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海和誉生物医药科技有限公司 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF FGFR3, FGFR1, FGFR4 SMN1; SMN2 4222/4885NPC1 2173/4885RAB9A 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.